Just thought I would share,

I just has my 4th - first session of UVB

I hope I'm doing the right thing by having more, it's always scary when a treatment stops.

But I'm trying to stay positive, I gave up smoking 6 weeks ago and I'm hoping this with the UVB will give me a longer remission

(the top of my back started to clear a little while ago!!)


just one Q, can my work force me to change my day off to fit one of the treatments in? UVB clinic is mon and Thurs my day off is Tues I work weekends too!!


x

The most poisonous substance on Earth could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases. Botox is already used medically in small doses to treat certain nerve disorders and facial wrinkles.

Edwin Chapman and colleagues explain that toxins, or poisons, produced by Clostridium botulinum bacteria, cause of a rare but severe form of food poisoning, are the most powerful toxins known to science.

Doctors can inject small doses, however, to block the release of the neurotransmitters, or chemical messengers, that transmit signals from one nerve cell to another. The toxins break down a protein in nerve cells that mediates the release of neurotransmitters, disrupting nerve signals that cause pain, muscle spasms and other symptoms in certain diseases. That protein exists not just in nerve cells, but in other cells in the human body. However, these non-nerve cells lack the receptors needed for the botulinum toxins to enter and work.

Chapman’s group sought to expand the potential use of the botulinum toxins by hooking it to a molecule that can attach to receptors on other cells.

Their laboratory experiments showed that these engineered botulinum toxins do work in non-nerve cells, blocking the release of a protein from immune cells linked to inflammation, which is the underlying driving force behind a range of diseases. Such botulinum toxin therapy holds potential in a range of chronic inflammatory diseases and perhaps other conditions, which could expand the role of these materials in medicine.

Get your favourite RSS reader. I use the Brief feed reader add-on with Firefox, but there are many others you can use and some email clients let you set them up.

Now you want your feeds. you can find them whilst on Psoriasis Club via your feed reader or you can click RSS Syndication at the foot of the home page and make your own. *Note: the latter will only find the thread version, to get the post version add 2 after syndication.

Now you choose which version you want:

This one gives you new threads: https://psoriasisclub.org/syndication.php?limit=15

This one gives you new posts: https://psoriasisclub.org/syndication2.php?limit=15

*Change the limit=** to the umber of threads/posts you want.

Click them and you will see the difference. *Note: Members only posts are shown if you are logged in. if you log out you will see the same as guests.

There you go you have the Psoriasis Club RSS feed.

Hi everyone,
Thought I would introduce myself and my Psoriasis story!!

I've had Psoriasis since I was 4years old (although after my flare cleared when I was 4 I only had it on my elbows for years)

When I was about 17 I had a major flare (I started training to be an aircraft engineer which was extremely stressful and my sister started to have suicidal tendencies another stress)

About the age of 20 my skin was doing well and was mainly affecting my knee's and elbows, but it wasn't to be for long

I'm now 26 and still covered in the stuff.

My treatments so far have been all the lotions and potions which turns out I'm allergic to pretty much all of them including things like E45 and diprobase, and any other cream starting with D
3 lots of UVB, 2 courses of methotrexate, and 2 courses of cyclosprin.
I'm starting another round of UVB on monday, I'm not expecting miricles just a little while of less vacumming!!

I left all my aircraft stuff behind as to stressful and I now work for an animal rescue center, I work with the dogs - training and rehoming and loving them.

I also have a wonderful Husband who is so supportive and helps me to stay strong in difficult times. I wouldn't say I'm totally depressed about my skin I don't mind so much especially in winter when it's ok to cover up I just need paper bags to come into fashion now for my face LOL

For me my challange now is just getting through the pain my skin brings me!


Hope to get to know some of you

Hanna x

When I'm Tweeting threads on @Psoriasisclub I sometimes like to think of something positive to tweet.

Here are a few I remember doing:

Quote:If I didn't have psoriasis I wouldn't know so many great people around the world

Quote:I may be flaky on the outside but just like you I'm soft in the middle

Quote:Psoriasis is not contagious you CAN use that shopping trolley after me. your hands will not fall off I promise!

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the receipt of verbal notification from the Food and Drug Administration (FDA) that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011. IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9 and is in clinical development as a potential therapy for autoimmune and inflammatory diseases.

“We are pleased to have the FDA’s notification that we can proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer of Idera. “We are now preparing for this Phase 2 trial of our novel dual-TLR antagonist for the treatment of autoimmune diseases and expect to initiate the study in the first half of 2012.”

Idera has selected psoriasis as the initial indication for the first clinical evaluation of IMO-3100 in patients with autoimmune disease. In July 2011, the company submitted a Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 12-week treatment period. As previously announced, this protocol was put on clinical hold by the FDA. In October 2011, the company submitted a new Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 4-week treatment period, for which the company has received notification of FDA authorization to proceed.

About IMO-3100
IMO-3100, an antagonist of TLR7 and TLR9, is a lead clinical candidate in development to treat autoimmune and inflammatory diseases. IMO-3100 is designed to block production of multiple cytokines induced through TLR7 and TLR9. In contrast, many current autoimmune disease treatments aim to block the activity of individual cytokines. IMO-3100 has demonstrated potent activity in reducing pathologic and immunologic manifestations in preclinical mouse models of diseases such as lupus, arthritis, psoriasis and hyperlipidemia. Phase 1 clinical trials of IMO-3100, including an escalating single-dose study and a multiple-dose study, have been completed in healthy subjects.

Source: iderapharma.com

If you want to follow Psoriasis Club on Twitter we are @Psoriasisclub

Please give us some mentions and RTs

If you follow us and you're a member of Psoriasis Club let us know so we can follow you back.

Thanks.

*Note we don't use Twitter to answer questions, please use the forum for that.

You have had psoriasis for a number of years and have tried all the prescribed treatments, you have tried all the over the counter drugs, you have tried a diet and life style change, you even fell for the con artist out there and parted with your hard earned cash trying to be rid of psoriasis.

One day you wake up with an idea buzzing around your head that you think could work. After all these years you hadn’t noticed that the cure for psoriasis was staring you in the face! You go about collecting the things you need to mix up a potion and after a few failed attempts; you think you have finally got it right.

OK let’s not get too carried away with it all. You have to try it first before telling anyone. So you start using your potion in small doses as well as keeping a diary of the trials. This goes on for about a year and you haven’t said a word to anyone.
So your potion works. After 2 months you were completely clear and had stopped taking the potion. You can’t believe it yourself so you share your potion with a trusted friend who also gets clear in two months.

You both remain clear and for around 5 years and decide you must share this with the world. But where to start? Should you form a company, should you get a patent, should you even try Dragons Den? Damn all this worry is enough to bring on a flare up. But it doesn’t, you are both still clear.

The cure that everyone has been looking for exists and you and your friend have it. You want to share it with the world for free, it’s easy to make at home and anyone with your instructions could make it. Your friend however wants to sell it and make lots of money; after all it’s got to be worth anyone with psoriasis paying €100 to be clear for the rest of their life.
Luckily you and your friend still get on very well and you both decide to sit down and discuss it. After a few days your friend tells you he has contacted four of the big drug manufacturers to ask if they would be interested in a psoriasis cure. You are livid; you wanted it to be free to the world and just wanted to see everyone cured of psoriasis. 

Within a few days you have offers from the big four drug companies, they are all interested but they all want it removed from the market. They have sent you and your friend an offer of One Hundred Million to remove it from the market, destroy any notes, and never talk about it again. If you break the contract they will take you to court for Two Hundred Million.

So what do you do? Would you say no to One Hundred Million, if you did could you trust your friend? Or would you just give it to the whole world for free and watch the big four drug manufacturers run it into the ground with false allegations about how your potion can kill people!

P.S No I haven’t developed a potion. If I had do you think I would be sitting here typing this with my stiff flaky fingers?

T Cells are like Soldiers in your body and their job is to protect you from Viruses, Infections and Foreign Substances.

Cell and Function
B-cell: Production of antibodies
Helper T cell: Helps B-cells in their function
Helper Th2: Helps B-cells
Helper Th1: Helps Cytotoxic T cells
Cytotoxic T cell: Kills and damages the antigens

The dutiful soldiers get into action the moment any foreign substance or agent enters our body. Thereby the immune system is activated. The end result is the elimination of the substance or agent from our bodies.

Usually your Soldiers will just go about their business without you knowing about it, but should you have psoriasis then things go wrong with your army.

Private T cell thinks he knows best and gets a bit carried away with his job. Somehow he gets in your skin, which is not his job. He spots a skin injury and off he goes! He stimulates B cells and other white blood cells into attack mode.
Also amongst his weapons he can stimulate the production of powerful immune factors called cytokines. In small amounts, cytokines are very important for healing. However, a high level of cytokines causes your skin cells to reproduce at a faster rate. This in turn creates a pile of dead skin that Private T Cell thinks are more enemies, and so the cycle begins.

Normally private T cell is very well regimented and obeys his orders, but you and me have inherited in our genetics, some rouge soldiers that have been waiting around for us to have a slight injury, emotional stress, or an infection so he can come out and go wild with his weapons.

Someone throw that soldier in the Cooler!

Hey everyone, been to see my parent's for a couple of weeks but glad to be back home.
Hope everyone is ok, I have had to endure numerous John Wayne films from my aged Father, so I have been bored stupid, but it is still nice to see them, and also nice to be home again.
Regards to all,
Micky.

A new study in Sweden shows high risk of pulmonary embolism in people with psoriasis and other autoimmune disorders.

Background:
Some autoimmune disorders have been linked to venous thromboembolism. We examined whether there is an association between autoimmune disorders and risk of pulmonary embolism.

Methods:
We followed up all individuals in Sweden without previous hospital admission for venous thromboembolism and with a primary or secondary diagnosis of an autoimmune disorder between Jan 1, 1964, and Dec 31, 2008, for hospital admission for pulmonary embolism. We obtained data from the MigMed2 database, which has individual-level information about all registered residents of Sweden. The reference population was the total population of Sweden. We calculated standardised incidence ratios (SIRs) for pulmonary embolism, adjusted for individual variables, including age and sex.

Findings:
535 538 individuals were admitted to hospital because of an autoimmune disorder. Overall risk of pulmonary embolism during the first year after admission for an autoimmune disorder was 6·38 (95% CI 6·19—6·57). All the 33 autoimmune disorders were associated with a significantly increased risk of pulmonary embolism during the first year after admission. However, some had a particularly high risk—eg, immune thrombocytopenic purpura (10·79, 95% CI 7·98—14·28), polyarteritis nodosa (13·26, 9·33—18·29), polymyositis or dermatomyositis (16·44, 11·57—22·69), and systemic lupus erythematosus (10·23, 8·31—12·45). Overall risk decreased over time, from 1·53 (1·48—1·57) at 1—5 years, to 1·15 (1·11—1·20) at 5—10 years, and 1·04 (1·00—1·07) at 10 years and later. The risk was increased for both sexes and all age groups.

Interpretation:
Autoimmune disorders are associated with a high risk of pulmonary embolism in the first year after hospital admission. Our findings suggest that these disorders in general should be regarded as hypercoagulable disorders.

Source: thelancet.com

In the dumps at the moment.I cannot believe this has happened to me in my 70s.i could cheerfully cut my head off.My scalp is giving me so much trouble.The Xamiol the Dr prescribed has made my head worse i have short fair hair and you would think i had been scalded.So now i have decided to stop all the treatment and see what happens.Also stopped the Dovobet on my body.The horrible red patches are sprouting up like mushrooms in the dark.Oh woe is me what a winge i am in fact family are calling me grumpy gertie

In its collaboration with Abbott, Biotest AG is pursuing an innovative therapeutic strategy to treat the autoimmune disorders Rheumatoid Arthritis and Chronic Plaque Psoriasis using the monoclonal antibody Tregalizumab (BT-061).

A phase IIa clinical trial with repeated doses has been completed in which Tregalizumab was tested for the treatment of chronic plaque psoriasis.

This trial was a placebo-controlled, double-blind, multicentre, multinational, multiple dose, dose-escalation study to evaluate the safety and efficacy of BT-061 in different doses and mode of administrations. Patients were treated subcutaneously or intravenously weekly for eight consecutive weeks in six different escalating dose groups. The primary endpoint of the study was PASI 75 (PASI : Psoriasis Area and Severity Index) response at Week 9, with PASI 50 and PASI 90 responses at Week 9 as secondary endpoints.

49 patients with Chronic Plaque Psoriasis were enrolled. Patients received Tregalizumab as monotherapy at doses between 25-100 mg as subcutaneous injections or 0.5 and 2 mg as intravenous infusions. Tregalizumab was administered once weekly for 8 weeks. In each treatment group, six patients received active treatment and two patients received placebo. After the treatment period, the patients were observed for further 12 weeks without Tregalizumab treatment (follow-up period).

Highest clinical response measured by the PASI score was achieved in the 100 mg dose-group. 71.4% of patients experienced at least a 50% improvement in psoriasis signs and symptoms as measured by PASI (PASI 50) at week 9, compared with 37.5% of those who received placebo. At the same time, in this dose-group, 42.9% of patients receiving active drug had an improvement of at least 75% (PASI 75) vs 12.5% for placebo.

In analogy to the results of the previous Phase I/II trial Study 967 (single dose administration), also in study 973 in the relevant active dose-groups, the PASI score generally further improved after the end of the 8 week treatment period. Further improvement of up to 90% (PASI 90) was observed in several patients during the treatment and follow-up period. The evaluation of response within the treatment and follow-up period (best response) showed a PASI 50 improvement in 71.4%, a PASI 75 in 57.1% and a PASI 90 in 14.3% of patients in the 100 mg SC dose-group. The respective numbers in the corresponding placebo group were 37.5%, 25.0%, and 0.0% (PASI 50, PASI 75, and PASI 90).

The good tolerability of Tregalizumab, which was expected based on the data from previous trials, has also been confirmed in the concluded phase IIa trial.

Further studies in Psoriasis in larger patient groups with a less frequent dosing schedule and a longer treatment period for Tregalizumab will only be started after finalisation of phase IIb trials in Rheumatoid Arthritis.

Source: pipelinereview.com

The LEO Pharma Research Foundation’s Gold and Silver awards 2011 go to Claus Johansen and Charlotte Menné Bonefeld – young researchers with exceptional achievements in dermatology.

The awards will be presented on 23 November at the Panum Institute in Copenhagen by Professor Povl Krogsgaard-Larsen, world-leading medicinal chemist and Chairman of the Board of the Carlsberg Foundation.

“This year’s award winners have made outstanding contributions to dermatology, despite their young age. Ultimately their research can lead to better care for patients with skin disorders. We hope that the awards can support their accomplishments in the future,” says Tore Duvold, chairman of LEO Pharma Research Foundation’s award selection committee.

Gold award:
The DKK 1,000,000 award goes to 38-year-old Danish dermatological researcher Claus Johansen. His research over the years has focused on the complex network of intra-cellular signals controlling inflammatory skin disorders, particularly in relation to psoriasis. The results have furthered understanding of the inflammatory process in psoriasis – key knowledge for the future development of new therapies.

Silver award:
The 36-year-old immunologist Charlotte Menné Bonefeld receives the DKK 500,000 award for her research achievements in dermatology. Her research includes new promising results, which show that the immune system weakens – in other words develops tolerance – when someone is repeatedly exposed to strong allergens such as those found in hair dyes. The results offer new insight into treatment possibilities and the reasons why people develop allergies.

Source: leo-pharma.com

Amgen announced today that a new U.S patent had been granted that could protect its big-selling drug Enbrel from generic competition for 17 more years.

Enbrel was one of several biotechnology drugs that were expected to face competition in the next few years from copycat versions, eventually saving the health care system billions of dollars a year.

The 2010 health care law established a way for such biologic drugs, which can cost tens of thousands of dollars a year, to face competition from near generic versions, which are often called biosimilars. A new law was needed because biologic drugs, which are made in living cells, were not covered by the 1984 law governing most pharmaceutical competition.

The main patent on Enbrel was to expire in October of next year. But the new patent could stave off such biosimilar competition until Nov. 22, 2028. By that time, Enbrel will have been on the market 30 years, far longer than the 20 years of protection expected in patent law.

Source: Amgen

LEO Pharma and Aarhus University have cloned the world’s first transgenic mini pig with a predisposition for psoriasis. The unique animal is expected to transform dermatological research and pave the way for safer and more effective skin treatments in the future.

Born in July, the pig was created using a new ‘handmade cloning’ technique pioneered in Denmark at Foulum Research Centre. The breakthrough offers new opportunities in the future for studying not only psoriasis, but also an array of skin diseases, from child eczema to skin cancer.

The successful result - part of a €6.4m project called Pigs and Health co-financed by the Danish National Advanced Technology Foundation ¬- will be presented in an all-day seminar at the Danish Agriculture and Food Council on 21 November in Copenhagen.

“This is an exciting breakthrough - not only for future psoriasis treatment, but also for the entire field of dermatological research,” says Thomas Kongstad Petersen, Director of Preclinical Development at LEO Pharma.

“Now we have the potential to test new drugs and therapies for a multitude of skin conditions, from eczema to skin cancer. We strongly believe that this animal will play a significant role in our future drug research and help us radically improve treatment for people with skin diseases.”

Cutting-edge cloning
The research also represents a globally significant advance in cloning, according to the research team at Aarhus University.

“The result is extremely promising. With this new discovery, we have established the genetic fundamentals for generating transgenic pig models of human skin disease”, says Jacob Giehm Mikkelsen, Associate Professor at the Department of Biomedicine, Aarhus University.

Thanks to the recent Danish progress in pig transgenesis – where this result is one of a series of breakthroughs - Denmark is now a global front runner in the production of cloned transgenic mini pigs by somatic cell nuclear transfer.

‘Handmade cloning’ involves removing an egg’s genetic material and replacing it with a genetically engineered somatic cell nucleus from a donor pig. The resulting egg is then transferred to a surrogate pig’s womb. To create the transgenic mini pigs with a predisposition for skin disease, the ‘handmade’ eggs were modified to carry two human genes. The next step is to standardise the animal model, which is expected to take up to two years.

Also involved in the Pigs and Health project are PixieGene, Danish Agriculture and Food Council, Pig Research Centre, University of Copenhagen, Technical University of Denmark and Ellegaard Göttingen Mini-pigs. The project aims to produce pigs that are sensitive to human disease for use in medical research.

Transgenetic means to have genetic material, or DNA, from another species.
A mini pig is raised under standardised conditions. For practical reasons, a mini pig therefore often used in scientific research and development of medicine.
‘Handmade cloning’ involves removing an egg’s genetic material and replacing it with a genetically engineered somatic cell nucleus from a donor pig. The resulting egg is then transferred to a surrogate pig’s womb.
Pigs are similar to humans in terms of physiology and anatomy, making them more suited for drug testing than mice or rats.
A somatic cell is a body cell i.e. from skin. 

Source: leo-pharma.com

BioTrends Survey of Over 1,300 Patients with Autoimmune Disorders Indicates High Disease Impact on Quality of Life Metrics and Challenges Patients Face with Their Disease.

In a comparison of patient reported ratings on autoimmune disease impact on quality of life metrics, BioTrends Research Group found that patients with ankylosing spondylitis (AS) and Lupus/SLE (SLE) reported significantly higher impact on “Activities of Daily Living” and “Emotional Health” compared to patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Leading up to diagnosis, patients reported struggling with symptoms for many months before receiving a diagnosis. About one-third of AS and PsA patients had symptoms for more than one year before being diagnosed and close to half of these patients saw more than two physicians before receiving a diagnosis. On average, AS patients were symptomatic for nearly three years, often receiving another diagnosis prior to AS. By comparison, PsA and RA patients were typically diagnosed within the first year of presentation and gout patients were diagnosed almost immediately.

The degree to which loved ones are involved in the care of these patients also varies by disease as does the extent to which the patients are active versus passive seekers of information. While the treating physician plays the lead role in providing disease information for all of the conditions, other sources also influence the patients in their awareness about their disease and treatment options.

Reports are based on surveys and qualitative interviews with patients diagnosed with various diseases including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, gout, chronic kidney disease, multiple sclerosis and hepatitis c. These reports seek to understand the patient journey from symptoms to diagnosis to current status. The reports also explore how often and in what ways patients seek information and probe into patient’s awareness about their disease, the treatments available and desired features in new treatment options.

Source: bio-trends.com

Objectives: 
To assess patients' preferences for psoriasis treatments and to identify the effect of sociodemographic and socioeconomic characteristics on these preferences.

Design:
A computer-based conjoint analysis experiment was conducted to analyze the preferences of individuals with moderate or severe psoriasis for outcome attributes (probability, magnitude, and duration of benefit, as well as probability, severity, and reversibility of adverse effects) and process attributes (treatment location, frequency, duration, delivery method, and individual cost) of psoriasis treatments. Relative importance scores (RISs) for each attribute were calculated. The effect of sociodemographic (age, sex, and marital status) and socioeconomic (income and employment) characteristics and Psoriasis Area and Severity Index and Dermatology Life Quality Index scores on preferences was assessed using analysis of variance, post hoc testing, and multivariate regression analysis.

Setting:
Outpatient dermatology clinic at a German university medical center.

Participants:
Patients with moderate or severe psoriasis (N = 163).

Main Outcome Measure: 
Relative importance scores for treatment attributes.

Results: 
The attribute considered to be most important in patients' preferences for psoriasis treatments was treatment location (RIS, 26.76), followed by probability of benefit (RIS, 23.77) and method of delivery (RIS, 23.49). The RISs for all process attributes were higher than for adverse effect–related attributes. Older individuals (≥65 years) were less concerned about the probability of benefit (β = –0.24; P = .005) compared with younger individuals.

Conclusions: 
When choosing among treatment options, individuals with psoriasis appear to be willing to accept treatment-related adverse effects to obtain process attributes compatible with their personal and professional life. Incorporating preferences in shared decision making may facilitate treatment adherence and optimize outcome.

Source: .ama-assn.org

It's a normal cause and effect reaction that when you get an itch, you scratch it. But for individuals with psoriasis, the "itchy" feeling can be taken to truly excruciating levels where scratching doesn't stop the itch and can may it even worse.

An array of prescription and over-the-counter (OTC) remedies specifically target the itch of psoriasis. This disorder is from an immune system glitch that causes skin cells to turn over much faster than normal, producing red, scaly skin lesions. To date, there is no cure for the disorder or the itching, only treatements.

The word psoriasis, in fact, is derived from the Greek word psora, meaning "itch," and alludes to one of the most troubling symptoms.

Although many people who have psoriasis (or "psoriatics") are disturbed by how the crusty lesions, or plaques, look -- particularly when they appear on the face and hands -- some are even more concerned with the itchiness.

For example, a 2004 study found that itching was the most frequent complaint among patients hospitalized for psoriasis, which can result in lesions on any area of the body, including the genitals, palms and soles of the feet.

Also, a survey of the National Psoriasis Foundation members indicated that only the scaling of lesions outranked the itch as the most vexing symptom of the condition.

Whenever a condition causes a chronic itch, it's likely to have an impact on quality of life. That's certainly the case with psoriasis, as evidenced by another scientific study. This study revealed that people with psoriasis reported various symptoms, including itchiness that disrupted their sleep, reduced their sex drive and interfered with their ability to concentrate.

However, many options are available to counter this uncomfortable symptom. Besides reducing discomfort, treatment can help avoid what's known as the "itch-scratch cycle," in which regular scratching can increase the inflammation, which leads to still more itching.

Moreover, scratching can actually trigger psoriasis flare-ups through the Koebner phenomenon, in which skin damage -- such as cuts, insect bites or sunburn -- elicits a disease response. This occurs in a wide range of psoriatics -- between 11% to 75%, depending on the study -- as well as in several other skin conditions.

In no particular order, here are some of the most common itch-fighters for psoriasis, including prescription, OTC and homemade preparations. Specific brand names may be mentioned because they're easy to find, but each of these remedies is sold under various labels. Consult a doctor about any unexpected reactions.

1) Antihistamines: These medications target the nerve pathways related to itching and can have a sedative effect, which may help psoriatics sleep through their itching. Look for "non-drowsy" antihistamines for daytime usage. Be sure to follow dosage guidelines.

2) Creams and lotions: The simple act of smoothing on a rich layer of emollients can help keep itch away, because dry skin tends to be itchy skin -- even in a person without psoriasis. Creams are more moisturizing than lotions. Certain anti-itch creams are particularly helpful for psoriasis, including Gold Bond Medicated Anti-Itch Cream and Aveeno Overnight Itch Relief (with oatmeal).

3) Topical corticosteroids: Whether in prescription or OTC strength, steroids -- such as Cortaid or Lanacort -- are widely used to treat various sorts of itching. However, you should exercise care in using these products. Over the long term, steroid creams can result in skin-thinning.

4) Capsaicin: An ingredient derived from hot peppers, capsaicin is proven to help itching, although for some it stings or burns at first. This product is available OTC, known as Capsin and Capzasin-P.

5) Topical anesthetics: An application of one of these nerve-deadening products can keep itch at bay for hours. Topical anesthetics include both prescription medications -- such as benzocaine and lidocaine -- and OTC products -- such as menthol and camphor -- found in Sarna lotion, Bengay and Vicks VapoRub.

6) Oatmeal baths: Especially for those with widespread plaques, oatmeal baths soothe all affected areas in one step. Just pour in the recommended amount of ground colloidal oatmeal (such as Aveeno Soothing Bath Treatment) as you fill up the tub and soak in its milky smoothness for awhile. Immediately after drying off, follow with a liberal layer of moisturizing cream for longer-lasting itch relief.

7) Ice packs: Among the quickest and easiest solutions, a frozen gel pack applied to psoriatic skin not only eases itch by numbing nerve endings, but cools the rawness of inflamed patches.

8) Plastic wrap over lotion: Covering psoriasis-covered areas with lotion and then plastic wrap, socks or gloves -- known as occlusion -- keeps medicated or nonmedicated preparations airtight for hours, increasing their itch-fighting effect and helping to discourage scratching. Check with a doctor to determine which preparations may work best for your case.